Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing ...

The blood–brain barrier, a selective, semipermeable border around the central nervous system, is the body’s built-in mechanism to protect these critical areas from unwanted intruders like toxins and ...

Intracellular Delivery via EV-based Approach (IDEA) was designed to efficiently package and deliver non-fused intracellular proteins to cytoplasmic or nuclear compartments to be functional. As a ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

New research from scientists at the Karolinska Institutet in Sweden and their collaborators elsewhere describes a way of improving extracellular vesicles’ ability to transport things like therapeutic ...

Grove Biopharma has raised a $30 million series A round to develop Bionic Biologics, also known as protein-like polymers (PLP), which were invented by Nathan Gianneschi at Northwestern University. A ...

Chronic diseases such as type 2 diabetes and inflammatory disorders are a major cause of disease burden and deaths around the world, but their treatment has proven difficult because there may not be ...

This article is based on a poster originally authored by Ebru Aydin Kurtulmus, Dagmar Hildebrand, Fiordiligie Casilag, Verena Banschbach, Jessica Heckmann, Sarah Schott, Marc Botcherby and Volker ...

Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments ...

New computer simulations that model every atom of a protein as it folds into its final three-dimensional form support the existence of a recently identified type of protein misfolding. Proteins must ...